Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
about
Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysCurrent status and perspectives of patient-derived xenograft models in cancer research.BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.Cell cycle proteins as promising targets in cancer therapyTargeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Therapeutic inhibition of BCL-2 and related family members.The MYCN Protein in Health and Disease.Family matters: How MYC family oncogenes impact small cell lung cancer.Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastomaJQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer.Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.Venetoclax is effective in small cell lung cancers with high BCL-2 expression.Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect.Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells.MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivityBCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer
P2860
Q28077848-8E15C39A-FAA8-4096-9198-C4679433AF75Q33667686-5001034D-A8E0-4AEF-9C36-5557454CEF5FQ37317126-435C5DAF-195E-46A0-8EA6-5F2245D0FFCCQ37665163-0EECCA41-5D7A-4E8E-9A2F-909C38B9AE84Q37693690-F1C25234-9A92-455F-88FB-56818A098834Q38722012-9D1EF906-0AB4-406D-9B18-49028D5B03FBQ39120136-F9B10773-9008-49EE-9444-87C87AE28E60Q39208675-69AF25FF-94AC-4E23-91C6-DDF1E232A1BAQ39454070-6E1ED73B-8229-4FCB-A705-2884A09EB5DDQ40553571-05FAD3BA-F440-4763-A6A8-BD1646D66629Q41616075-4362A252-AAA7-4A83-8822-A48EF8813D90Q42282780-898F48A2-FC1B-4C0A-A2E0-4CC7E7379A20Q44268034-1143BAC7-DA40-47A0-9C21-67816657847DQ45070526-0058FBDE-B79B-4DA2-8228-BF293E438742Q45072361-6C8B4931-D0CC-4876-98E4-104ADFBE7BA4Q47671054-2875DC50-6049-4D89-B2A8-2A8503DD3067Q50145710-B6D88EBF-1DC9-4127-87B8-6703EABF1B7FQ50962833-0F89C740-544D-41D3-AF35-99267DC16DE7Q51392646-43EC2F29-F92D-4A47-B941-0AC85C086088Q52370039-16A7DCB7-049B-42FA-A6EE-DB8E04724B1CQ52714608-31CF4CFD-5BA6-4091-BE0B-CBFD17AE54A9Q54979940-5E357CE9-3577-4665-8B57-277EAC666721Q55447462-8E7B4483-D3E7-4420-9176-02C06A09A89DQ58695490-B46EAFBE-ED14-4EC3-9946-E40E10257288Q58779838-3478179D-DF1D-40AE-AA18-69D71CC6D745
P2860
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
description
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2016
@ast
im Februar 2016 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2016/02/08)
@sk
vědecký článek publikovaný v roce 2016
@cs
wetenschappelijk artikel (gepubliceerd op 2016/02/08)
@nl
наукова стаття, опублікована в лютому 2016
@uk
مقالة علمية (نشرت في 8-2-2016)
@ar
name
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@ast
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@en
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@nl
type
label
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@ast
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@en
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@nl
prefLabel
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@ast
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@en
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@nl
P2093
P2860
P50
P3181
P1433
P1476
Exploitation of the Apoptosis- ...... c Targeted Therapy Combination
@en
P2093
Anahita Dastur
Anthony C Faber
Brad E Windle
Carlotta Costa
Charles T Jakubik
Craig Yates
Cyril H Benes
Daniel A R Heisey
Erin M Sennott
Hisashi Harada
P2860
P304
P3181
P356
10.1016/J.CCELL.2016.01.002
P577
2016-02-01T00:00:00Z